Fulcrum Therapeutics (NASDAQ:FULC) Price Target Increased to $17.00 by Analysts at The Goldman Sachs Group
Fulcrum Therapeutics (NASDAQ:FULC) Price Target Increased to $17.00 by Analysts at The Goldman Sachs Group
Fulcrum Therapeutics (NASDAQ:FULC – Get Rating) had its price objective boosted by The Goldman Sachs Group from $11.00 to $17.00 in a research note published on Thursday, Benzinga reports. They currently have a buy rating on the stock.
據Benzinga報道，支點治療公司(納斯達克代碼：FULC-GET評級)在週四發佈的一份研究報告中，將高盛的目標價從11.00美元上調至17.00美元。他們目前對該股的評級為買入。
Several other research firms have also recently weighed in on FULC. Morgan Stanley lifted their price target on Fulcrum Therapeutics from $25.00 to $26.00 and gave the stock an overweight rating in a report on Monday, November 14th. Credit Suisse Group lowered their price target on Fulcrum Therapeutics from $22.00 to $19.00 and set an outperform rating for the company in a report on Wednesday, November 9th. Stifel Nicolaus lowered their price target on Fulcrum Therapeutics from $43.00 to $35.00 in a report on Thursday, October 20th. Oppenheimer reduced their price objective on Fulcrum Therapeutics to $30.00 in a research report on Tuesday, November 15th. Finally, Piper Sandler reduced their price objective on Fulcrum Therapeutics from $42.00 to $18.00 in a research report on Tuesday, November 8th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of Moderate Buy and an average price target of $23.00.
其他幾家研究公司最近也對FULC發表了看法。摩根士丹利在11月14日星期一的一份報告中將支點治療公司的目標價從25.00美元上調至26.00美元，並給予該股加碼評級。瑞士信貸集團在11月9日週三的一份報告中將Fulcrum Treeutics的目標價從22.00美元下調至19.00美元，併為該公司設定了表現優於大盤的評級。Stifel Nicolaus在10月20日星期四的一份報告中將他們對Fulcrum治療公司的目標價從43.00美元下調至35.00美元。奧本海默在11月15日星期二的一份研究報告中將他們對Fulcrum治療公司的目標價格下調至30.00美元。最後，派珀·桑德勒在11月8日星期二的一份研究報告中將他們對Fulcrum治療公司的目標價格從42.00美元下調至18.00美元。一位研究分析師對該股的評級為持有，六位分析師對該公司的評級為買入。根據MarketBeat的數據，該公司目前的共識評級為適度買入，平均目標價為23.00美元。
Fulcrum Therapeutics Stock Up 4.0 %
支點治療公司股票上漲4.0%
FULC stock opened at $12.63 on Thursday. The business has a 50 day moving average price of $7.91 and a two-hundred day moving average price of $7.36. The company has a market cap of $657.40 million, a price-to-earnings ratio of -4.93 and a beta of 1.90. Fulcrum Therapeutics has a twelve month low of $3.21 and a twelve month high of $24.79.
FULC股價週四開盤報12.63美元。該業務的50日移動均線價格為7.91美元，200日移動均線價格為7.36美元。該公司市值為6.574億美元，市盈率為-4.93倍，貝塔係數為1.90。FULCRUM治療公司的12個月低點為3.21美元，12個月高位為24.79美元。
Insiders Place Their Bets
內部人士下注
In other news, major shareholder Ra Capital Management, L.P. acquired 1,341,420 shares of the business's stock in a transaction on Friday, December 16th. The shares were purchased at an average cost of $5.42 per share, with a total value of $7,270,496.40. Following the acquisition, the insider now directly owns 9,403,049 shares of the company's stock, valued at $50,964,525.58. The transaction was disclosed in a document filed with the SEC, which is available through this link. In related news, CEO Robert J. Gould sold 6,766 shares of the business's stock in a transaction dated Friday, January 13th. The shares were sold at an average price of $15.00, for a total value of $101,490.00. Following the transaction, the chief executive officer now directly owns 499,864 shares of the company's stock, valued at approximately $7,497,960. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Ra Capital Management, L.P. acquired 1,341,420 shares of the stock in a transaction that occurred on Friday, December 16th. The stock was purchased at an average price of $5.42 per share, for a total transaction of $7,270,496.40. Following the completion of the purchase, the insider now directly owns 9,403,049 shares in the company, valued at approximately $50,964,525.58. The disclosure for this purchase can be found here. Insiders have bought 2,449,599 shares of company stock valued at $13,695,667 in the last three months. 14.50% of the stock is currently owned by insiders.
在其他新聞方面，大股東Ra Capital Management，L.P.在12月16日星期五的一次交易中收購了該公司1,341,420股股票。這些股票是以每股5.42美元的平均成本購買的，總價值為7270,496.40美元。收購完成後，這位內部人士現在直接持有該公司9,403,049股股票，價值50,964,525.58美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的，該文件可通過這個環節。在相關新聞中，首席執行官羅伯特·J·古爾德在日期為1月13日(星期五)的交易中出售了6766股該公司股票。這些股票的平均價格為15.00美元，總價值為101,490.00美元。交易完成後，這位首席執行官現在直接持有該公司499,864股股票，價值約7,497,960美元。這筆交易是在提交給美國證券交易委員會的一份法律文件中披露的，該文件可通過這個環節。此外，大股東Ra Capital Management，L.P.在12月16日星期五的交易中收購了該公司1,341,420股股票。股票是以每股5.42美元的平均價格購買的，總交易額為7270,496.40美元。收購完成後，該內部人士現在直接擁有該公司9,403,049股，價值約50,964,525.58美元。關於這次購買的披露可以找到這裏。在過去的三個月裏，內部人士購買了2,449,599股公司股票，價值13,695,667美元。該公司14.50%的股份目前由內部人士持有。
Institutional Investors Weigh In On Fulcrum Therapeutics
機構投資者看好Fulcrum治療公司
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Sandia Investment Management LP bought a new stake in Fulcrum Therapeutics in the 3rd quarter valued at about $40,000. Delphia USA Inc. bought a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth $58,000. SG Americas Securities LLC lifted its holdings in shares of Fulcrum Therapeutics by 207.1% during the 2nd quarter. SG Americas Securities LLC now owns 13,173 shares of the company's stock worth $65,000 after acquiring an additional 8,884 shares during the last quarter. AQR Capital Management LLC bought a new stake in shares of Fulcrum Therapeutics during the 2nd quarter worth $68,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Fulcrum Therapeutics during the 3rd quarter worth $74,000.
對衝基金和其他機構投資者最近增持或減持了該公司的股份。Sandia Investment Management LP在第三季度購買了Fulcrum Treateutics的新股份，估值約為4萬美元。德爾菲亞美國公司在第二季度購買了支點治療公司價值5.8萬美元的新股。SG America Securities LLC在第二季度增持了207.1%的Fulcrum Treateutics股票。SG America Securities LLC在上個季度增持了8,884股後，現在擁有13,173股該公司股票，價值65,000美元。AQR Capital Management LLC在第二季度購買了Fulcrum治療公司價值6.8萬美元的新股份。最後，AllSpring Global Investments Holdings LLC在第三季度購買了Fulcrum治療公司價值74,000美元的新股份。
About Fulcrum Therapeutics
關於支點治療公司
(Get Rating)
(獲取評級)
Fulcrum Therapeutics, Inc is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T.
支點治療公司是一家臨牀階段的生物製藥公司。該公司開發新藥，並專注於解鎖基因控制機制，以開發小分子療法。它的候選產品包括losmapimod和FTX-HBF。該公司由邁克爾·R·格林、丹尼·萊因伯格、魯道夫·雅尼施、珍妮·T。
Featured Stories
專題報道
- Get a free copy of the StockNews.com research report on Fulcrum Therapeutics (FULC)
- Which Wireless Stock Should You Buy in 2023?
- Is Virgin Galactic Stock Preparing for Lift-Off?
- Chevron is Likely to Increase its Dividend Before Earnings
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- 免費獲取StockNews.com關於Fulcrum治療(FULC)的研究報告
- 2023年你應該購買哪些無線股票？
- 維珍銀河股票準備起飛了嗎？
- 雪佛龍可能在盈利前增加派息
- 市場回顧周-1/16-1/20
- Old Dominion是否表明Trucking正在踩剎車？
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
獲得《支點治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Fulcrum治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。